PubRank
Search
About
Ipilimumab, Nivolumab, and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Clinical Trial ID NCT01896999
PubWeight™ 9.29
‹?›
🔗 Visit the ClinicalTrials.gov page for NCT01896999
Top papers
Rank
Title
Journal
Year
PubWeight™
‹?›
1
Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy.
Oncoimmunology
2014
1.22
2
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications.
Oncoimmunology
2015
1.06
3
Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander".
Toxins (Basel)
2014
0.92
4
Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers.
Hum Vaccin Immunother
2016
0.89
5
The past, present and future of immunotherapy against tumor.
Transl Lung Cancer Res
2015
0.85
6
Customized targeted therapy in Hodgkin lymphoma: hype or hope?
Hematol Oncol Clin North Am
2014
0.82
7
Oncogene withdrawal engages the immune system to induce sustained cancer regression.
J Immunother Cancer
2014
0.80
8
Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?
Bone Marrow Transplant
2015
0.77
9
Relapsed Hodgkin lymphoma: management strategies.
Curr Hematol Malig Rep
2014
0.76
10
Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.
Lancet Haematol
2020
0.75
11
Treatment of relapsed classical Hodgkin lymphoma in the brentuximab vedotin era.
Hematology Am Soc Hematol Educ Program
2014
0.75
12
Recent advances in the management of Hodgkin lymphoma.
F1000Res
2016
0.75
Next 100